InvestorsHub Logo
Post# of 253594
Next 10
Followers 839
Posts 120721
Boards Moderated 13
Alias Born 09/05/2002

Re: DewDiligence post# 198251

Monday, 12/14/2015 8:02:56 PM

Monday, December 14, 2015 8:02:56 PM

Post# of 253594
RBC cut its price target on ESPR from $65 to $40—presumably based on the negative FDA panel vote on Vytorin (#msg-119157187):


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.